APTA Therapeutics ist ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf die Entwicklung innovativer, Aptamer-basierter Therapien von Krankheiten fokussiert, die mit regulatorischen Autoantikörpern assoziiert sind. Die wissenschaftlichen Wurzeln befinden sich bei zwei der renommiertesten Berliner Forschungsinstitutionen: Charité, Universitätsmedizin Berlin und Max Delbrück Centrum für Molekulare Medizin (MDC).
Unsere Kerntechnologie nutzt die Vielseitigkeit und Präzision von DNA-basierten Aptameren, um die Aktivität pathogener regulatorischer Autoantikörper zu blockieren oder zu modulieren. Generell können Aptamere mit hoher Affinität und Spezifität an verschiedenste Ziele binden – Proteine, Peptide oder ganze lebende Zellen. Verglichen mit Antikörpern bieten Aptamere zahlreiche Vorteile: ein breiteres Zielmolekülspektrum, bessere thermische Stabilität, geringeres Molekulargewicht und leichtere Modifizierbarkeit. Daher gelten sie als vielversprechende neue Wirkstoffklasse mit therapeutischem Potenzial für ein breites Spektrum von Erkrankungen.
APTA Therapeutics ist ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf die Entwicklung innovativer, Aptamer-basierter Therapien von Krankheiten fokussiert, die mit regulatorischen Autoantikörpern assoziiert sind. Die wissenschaftlichen Wurzeln befinden sich bei zwei der renommiertesten Berliner Forschungsinstitutionen: Charité, Universitätsmedizin Berlin und Max Delbrück Centrum für Molekulare Medizin (MDC).
Unsere Kerntechnologie nutzt die Vielseitigkeit und Präzision von DNA-basierten Aptameren, um die Aktivität pathogener regulatorischer Autoantikörper zu blockieren oder zu modulieren. Generell können Aptamere mit hoher Affinität und Spezifität an verschiedenste Ziele binden – Proteine, Peptide oder ganze lebende Zellen. Verglichen mit Antikörpern bieten Aptamere zahlreiche Vorteile: ein breiteres Zielmolekülspektrum, bessere thermische Stabilität, geringeres Molekulargewicht und leichtere Modifizierbarkeit. Daher gelten sie als vielversprechende neue Wirkstoffklasse mit therapeutischem Potenzial für ein breites Spektrum von Erkrankungen.
APTA Therapeutics glaubt fest an das therapeutische Potenzial und die Vielseitigkeit von DNA-basierten Aptameren als neuartige Therapien für Erkrankungen, die mit regulatorischen Autoantikörpern (RAb-GPCRs) assoziiert sind.
Wir sind bestrebt, in Verbindung mit verbesserter Diagnostik eine führende Rolle bei aptamer-basierten Therapien zu spielen, die personalisierte Medizin voranbringen und damit wirksamere Therapien für Indikationen mit hohem ungedecktem Bedarf ermöglichen.
Unser wissenschaftlicher Beirat besteht aus weltweit führenden Experten, die unser Engagement für verbesserte globale Gesundheit und lebensverändernde Therapien teilen.
CEO & Co-Founder
Dr. Oliver von Stein is a serial entrepreneur and has founded and managed several biotech companies with a focus on nucleic acid-based therapies.
Dr. von Stein has more than 25 years of C-level operational experience in the biotech industry in the areas of corporate and business development and has held various high-level positions in the pharmaceutical industry.
Dr. von Stein has a solid track record of closing deals on drug and diagnostic assets, raising capital from national and international institutions and successfully growing companies.
He is listed as an inventor on over 70 patents and patent applications in the field of nucleic acid-based drug development and diagnostics and has published numerous scientific papers in leading journals and holds a PhD in molecular genetics from the Karlsruhe Institute of Technology.
CMO & Co-Founder
Dr. Axel Mescheder, M.D has 30+ years of clinical development and regulatory experience with a track record of advancing clinical development programs to product registrations and commercialization both Europe and the United States.
Prior to joining APTA Therapeutics, Dr. Mescheder held various C-level positions in biotechnology companies.
Dr. Mescheder’s therapeutic focus is on immunology and inflammation, infectious diseases and oncology.
Dr. Mescheder is member of leading international medical associations including ASCO, ESMO, ESCMID, DGPharMed/IFAPP and he supports BioM/Martinsried as a mentor for biotech start-up companies and Young Professionals.
Dr. Mescheder is a board-certified M.D. from the University of Kiel (Germany), and is author and co-author of numerous peer-reviewed publications.
CSO/COO
Dr. Daniel Bock has been in pharmaceutical R&D for more than 25 years. His expertise spans early drug discovery, non-clinical programs, and clinical development, with a focus on immunomodulatory drugs, including small molecules and oligonucleotides. He started his career at Novartis before joining and building up Revotar Biopharmaceuticals, where he served in different roles, ultimately as CSO. Alongside ongoing consultancy in the biotech space, he was most recently CSO at sterna biologicals. Dr. Bock holds a Ph.D. in Biology from the University of Hannover, Germany.
MD, PhD, FESC, FHFA
Professor of Cardiomyopathies and Head of the Centre for Heart Failure Research, Department of Cardiology, Maastricht University.
Served as a chairperson for several prestigious boards, committees and work/study groups in the European Society of Cardiology.
He is (and has been) the chair of different European committees and working groups in the field of myocarditis and cardiomyopathies and is a board member of the ESC Heart Failure Association, ESC Working Group of Myocardial Function, ESC Heart Failure Association Committee on Diastolic Heart Failure and ESC Heart Failure Association Committee on Translational Research.
OBE, BSc, MB, ChB, MD, FRCP, FRSE, FMedSci, FESC, FACC, FAHA, FJCS, FHFA, FHFSA, FBSH
Professor McMurray is currently Professor of Medical Cardiology and honorary Consultant Cardiologist at the Queen Elizabeth University Hospital, Glasgow.
Professor McMurray is an Associate Editor for JACC-Heart Failure and is also a member of the editorial board of several journals including the European Journal of Heart Failure, Diabetes Care and the New England Journal of Medicine, and Guest Editor for Circulation & Circulation: Heart Failure.
He has won several awards, and in June 2015, Professor John McMurray and Professor Salim Yusuf (McMaster University, Hamilton Ontario, Canada) were jointly awarded the 8th Arrigo Recordati International Prize for Scientific Research (for outstanding contributions in secondary prevention and risk reduction strategies in patients with cardiovascular diseases). He is also the recipient of the Louis and Artur Lucian Award for Research in Circulatory Diseases.
Professor McMurray was awarded an (honorary) OBE in 2019 by Her Majesty the Queen, in recognition of his services to cardiovascular research. In 2020 he was awarded the Gold Medal of the European Society of Cardiology, which the society describes as “the highest honour it can bestow on exceptional scientists for their contribution to cardiovascular medicine”.
Professor McMurray has published extensively in the field of cardiology and has been invited to lecture widely at many international congresses and delivered many several named lectures.
MD
Professor of Internal Medicine Hemato-oncology and Clinical Immunology. Deputy Director of the Institute of Medical Immunology at the Charité Universitätsmedizin in Berlin, Germany. Co-founder of the COST-funded European network for ME/CFS EUROMENE and the Post COVID Network Charité.
In 2022, she was awarded the Federal Cross of Merit for her commitment to ME/CFS.
MD, PhD
Professor of Neuroimmunology and serves as Vice-Dean of Clinical Research at the Charité and as director of the Experimental and Clinical Research Center (ECRC) and leader of the Clinical Neuroimmunology department of the NeuroCure.
He is also an associate Editor Neurology Neuroimmunology and Neuroinflammation and serves as a medical consultant for Science Council (BfArM).
He has also been involved in a number of scientific activities including MS‐Subcommittee of the European Neurological Society (ENS) (since 2008), Member, Editorial Board, EPMA Journal (since 2009), Associate Editor “Neurology: Neuroimmunology and Neuroinflammation” (since 2015) and Medical Consultant for EU‐ Announcements for Research Programs on Rare Diseases (E‐RARE) (since 2016).
